LeMaitre Vascular Inc (NASDAQ:LMAT) has been assigned an average rating of “Hold” from the nine ratings firms that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $34.80.
A number of equities analysts have recently issued reports on the company. Zacks Investment Research downgraded LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Thursday. Roth Capital upgraded LeMaitre Vascular from a “neutral” rating to a “buy” rating and dropped their price target for the stock from $39.00 to $34.00 in a research note on Monday, October 8th. BidaskClub downgraded LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. Finally, ValuEngine downgraded LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Thursday, November 1st.
In related news, Director Michael H. Thomas sold 20,000 shares of the firm’s stock in a transaction on Tuesday, October 30th. The stock was sold at an average price of $27.93, for a total value of $558,600.00. Following the transaction, the director now directly owns 20,000 shares of the company’s stock, valued at approximately $558,600. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 20.30% of the stock is currently owned by company insiders.
Shares of LMAT stock traded down $0.59 on Friday, reaching $26.01. The stock had a trading volume of 183,100 shares, compared to its average volume of 146,816. The company has a market cap of $520.88 million, a P/E ratio of 30.70, a price-to-earnings-growth ratio of 2.17 and a beta of 1.00. LeMaitre Vascular has a 1 year low of $25.63 and a 1 year high of $41.28.
LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Friday, October 5th. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.21. The firm had revenue of $24.17 million for the quarter, compared to the consensus estimate of $26.06 million. LeMaitre Vascular had a return on equity of 18.07% and a net margin of 20.52%. Sell-side analysts expect that LeMaitre Vascular will post 1.02 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 6th. Stockholders of record on Tuesday, November 20th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Monday, November 19th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 1.08%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 32.56%.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.